# Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients

> **NCT02642913** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Enzalutamide with Sorafenib

## Key facts

- **NCT ID:** NCT02642913
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-03-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02642913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02642913, "Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02642913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*